ATE416766T1 - Verfahren zur herstellung von 4-(2- dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on- hydrochlorid - Google Patents

Verfahren zur herstellung von 4-(2- dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on- hydrochlorid

Info

Publication number
ATE416766T1
ATE416766T1 AT04806731T AT04806731T ATE416766T1 AT E416766 T1 ATE416766 T1 AT E416766T1 AT 04806731 T AT04806731 T AT 04806731T AT 04806731 T AT04806731 T AT 04806731T AT E416766 T1 ATE416766 T1 AT E416766T1
Authority
AT
Austria
Prior art keywords
indol
dihydro
dipropylaminoethyl
hydrochloride
producing
Prior art date
Application number
AT04806731T
Other languages
English (en)
Inventor
Venkatasubramanian Radha Tarur
Dhananjay Govind Sathe
Harish Kashinath Mondkar
Rajesh Ganpat Bhopalkar
Samadhan Daulat Patil
Original Assignee
Usv Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Ltd filed Critical Usv Ltd
Application granted granted Critical
Publication of ATE416766T1 publication Critical patent/ATE416766T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT04806731T 2004-01-20 2004-07-16 Verfahren zur herstellung von 4-(2- dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on- hydrochlorid ATE416766T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN60MU2004 2004-01-20

Publications (1)

Publication Number Publication Date
ATE416766T1 true ATE416766T1 (de) 2008-12-15

Family

ID=34746665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04806731T ATE416766T1 (de) 2004-01-20 2004-07-16 Verfahren zur herstellung von 4-(2- dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on- hydrochlorid

Country Status (11)

Country Link
US (1) US7378439B2 (de)
EP (1) EP1706113B1 (de)
JP (1) JP2007518793A (de)
KR (1) KR20060130108A (de)
CN (1) CN1909901A (de)
AT (1) ATE416766T1 (de)
AU (1) AU2004313729A1 (de)
CA (1) CA2548982A1 (de)
DE (1) DE602004018386D1 (de)
PL (1) PL1706113T3 (de)
WO (1) WO2005067922A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2513055A1 (de) 2009-12-16 2012-10-24 Pharmathen S.A. Verfahren zur herstellung von ropinirol und salzen daraus
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
EP2688561B1 (de) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermale zusammensetzungen mit einer wirkstoffschicht und einer wirkstoffumwandlungsschicht
EP2776020B1 (de) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Verfahren zur behandlung von neoplasmen der haut
PL2797416T3 (pl) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
CN103086946B (zh) * 2013-01-17 2018-10-23 浙江华海药业股份有限公司 一种盐酸罗匹尼罗纯化的方法
EP2968299B1 (de) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Verbindungen und verwendungen davon zur modulation von hämoglobin
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10961194B2 (en) 2017-06-16 2021-03-30 Zhejiang Huahai Licheng Pharmaceutical Co., Ltd. Method for purifying ropinirole hydrochloride
EP3860975B1 (de) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulatoren von hämoglobin zur behandlung von sichelzellenanämie
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
US5958965A (en) * 1996-08-27 1999-09-28 American Home Products Corporation 4-aminoethoxy indoles

Also Published As

Publication number Publication date
KR20060130108A (ko) 2006-12-18
AU2004313729A1 (en) 2005-07-28
US7378439B2 (en) 2008-05-27
EP1706113A1 (de) 2006-10-04
CN1909901A (zh) 2007-02-07
EP1706113B1 (de) 2008-12-10
US20050159605A1 (en) 2005-07-21
JP2007518793A (ja) 2007-07-12
PL1706113T3 (pl) 2009-07-31
CA2548982A1 (en) 2005-07-28
DE602004018386D1 (de) 2009-01-22
WO2005067922A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
DE602004018386D1 (de) Verfahren zur herstellung von 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on-hydrochlorid
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE602004031895D1 (de) Verfahren zur Herstellung von Dichlorpropanol
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
CN104059013B8 (zh) 1-芳基-3-氮杂二环[3.1.0]己烷:其制备方法和用于治疗神经精神障碍的用途
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
DE60129518D1 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
MY153719A (en) Prokineticin 1 receptor antagonists
DE60316152D1 (de) Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
WO2007081995A3 (en) Urotensin ii receptor antagonists
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
DE602005014280D1 (de) Verfahren zur herstellung von ä1,4,5ü-oxadiazepinderivaten
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
ATE347543T1 (de) Verfahren zur herstellung der enantiomeren formen von cis-konfigurierten 1,3-cyclohexandiol- derivaten
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
DE602005017194D1 (de) Verfahren zur herstellung von carvedilol und seinen enantiomeren
DE602005002776D1 (de) Verfahren zur Herstellung von 1,3-Dihydro-2H-3-Benzazepin-2-on und Anwendung zur Herstellung von Ivabradine und ihren pharmazeutischen annehmbaren Salzen
EP1720840A4 (de) Verfahren zur herstellung von 1,3-dioxolannukleosiden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties